"Clinical Studies of Hemassist."

According to an abstract submitted by the author to the 7th International Symposium on Blood Substitutes (7-ISBS), held September 7-10, 1997; in Tokyo, Japan, "HemAssist(TM) (a 10% solution of diaspirin cross-linked hemoglobin) in lactated electrolyte is a modified human hemoglobin therapeutic that has been under clinical evaluation since 1992. Twelve separate patient studies have been completed and three Phase III trials are in progress. The early Phase II trials evaluated the pharmacodynamic effects of this new product in surgical, stroke, intensive care, and hemodialysis patient populations. Later protocols used larger doses in cardiac, orthopedic and general surgery. (A pivotal...

Want to see the full article?

• Purchase this article for only $3.00